

**Express Mail No.: EL 500 575 175 US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Siegall *et al.*

Serial No.: 09/724,409

Filed: November 28, 2000

For: NUCLEIC ACIDS ENCODING ANTI-CD40  
PROTEINS AND METHODS OF PRODUCING  
RECOMBINANT ANTI-CD40 PROTEINS

Confirmation No.: 9908

Examiner: Karen A. Canella

Group Art Unit: 1642

Attorney Docket No.: 9632-014

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references CF and CG listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references CF and CG are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited".

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c)(2), since this Supplemental Information Disclosure Statement is being submitted after the first Office Action on merits but before a final Office Action under 37 C.F.R. § 1.113, a fee of \$180.00 is believed to be due. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date: September 30, 2002

Adriane M. Antler 32,605  
Adriane M. Antler (Reg. No.)

By: Muna Abu-Shaar  
Muna Abu-Shaar  
Limited Recognition Under 37 C.F.R. § 10.9(b)  
Copy of Certificate Enclosed

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures

EXPRESS MAIL NO.: EL 500 575 175 US

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)				ATTY. DOCKET NO.		APPLICATION NO.	
				9632-014		09/724,409	
				APPLICANT			
				Siegal et al.		GROUP	
				FILING DATE		1642	
				November 28, 2002			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	CF	Hirano et al., 1999, "Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand", Blood, 93(9):2999-3007.					
	CG	Kwekkeboom et al., 1994, "Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction", Eur. J. Immunol. 24:508-517.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							